



Molecular Formula: $C_{167}H_{252}N_{42}O_{55}$
Molecular Weight: 3728.03618
HisSerGlnGlyThrPheThrSerAspLys[Glu.C(O)C16]SerGluTyrLeuAspSerG
luArgAlaArgAspPheValAlaTrpValGluAlaGlyGly (SEQ ID NO:4)

FIG. 1

FIG. 2



ABPM = ambulatory blood pressure monitoring; CGM = continuous glucose monitoring; n= number of subjects; V = visit.




Mean glucose (mg/dL) (±SE)
300
280
260
240
220
200
180
160
140
120
100
0
15
30
45
60
90
120
180
240
Minutes Post Meal
Day -5
Day 32
Placebo
MEDI0382
Placebo
MEDI0382
ITT = intent-to-treat; MMTT = mixed meal tolerance test

FIG. 3

FiG. 4



BL = Baseline; ITT = intent-to-treat; SE = standard error



Placebo
% time spent
100
90
80
70
60
50
40
30
20
10
0
0.66
2.73
44.89
37.39
<54 mg/dL
<70 mg/dL
70-180 mg/dL
>180 mg/dL
Glucose Range
MEDI0382
% time spent
100
90
80
70
60
50
40
30
20
10
0
2.01
6.07
78.67
10.5
<54 mg/dL
<70 mg/dL
70-180 mg/dL
>180 mg/dL
Glucose Range

FIG. 5



Diminishing hypoglycaemia in cotadutide arm due to insulin dose adjustments
% time spent < 3.0 mmol/l (54 mg/dL)
0
1
2
3
4
Baseline
50 µg
100 µg
200 µg
300 µg

FIG. 6

FIG. 7




Follow-up
Placebo
MEDI0382
UACR change from baseline (mg/g): mean +/- SE
100
80
60
40
20
0
-20
-40
-60
-80
-100
-120
-140
0
5
10
15
20
25
30
35
40
day on treatment

FIG. 8


Mean Change in eGFR (±SE) (mL/min/1.72m²)
10
8
6
4
2
0
-2
-4
-6
-8
-10
Baseline
5
12
19
3233
40
60
Day
Placebo
MEDI0382



PKconc (ng/mL), Geometric Mean (ng/mL)
20
15
10
5
0
Day 1
Day 5
Day 12
Day 19
Day 32
Day 33
VISIT
PKconc vs VISIT
GeometricMean vs VI...

FIG. 9




Mean Change from Baseline in Total Daily Insulin Dose (U/day)
10
0
-10
-20
-30
-40
4
11
18
32
40
Day
Placebo
MEDI0382

FIG. 10

FIG. 11


Cohort 1
12 Week Primary Analysis
28 days
10 to 14 days
Run In
Screening
26 weeks
Treatment Period
28 days
Follow-up
Cotadutide QD titrated to 100 µg N=45
Cotadutide QD titrated to 300 µg N=45
Cotadutide QD titrated to 600 µg N=45
Placebo QD N=45
Semaglutide QW titrated to 0.5 mg N=45
Primary endpoint:
• Fold change from baseline in UACR to the end of 12 weeks of dosing in Cohort 1
Key I/E criteria:
• T2DM
• eGFR ≥ 20-90 ml/min/ 1.73 m² with micro/ macroalbuminuria
• On SGLT2i (≥ 40%)
• +/- MF
• Washout SU or glitinide
• +/- Insulin
• Exclude T1DM
CGM
UACR (3 x first morning void samples)
UACR (3 x first morning void samples)
UACR (3 x first morning void samples)
Placebo participants will follow the same titration steps as those randomised to cotadutide.
They will be distributed evenly across each of the 3 arms.
Cohort 2
28 days
10 to 14 days
Run In
Screening
26 weeks
Treatment Period
28 days
Follow-up
Cotadutide QD titrated to 600 µg N=9
Placebo QD N=3
CGM
UACR (3 x first morning void samples)
UACR (3 x first morning void samples)
UACR (3 x first morning void samples)
Cohort 2 will run only in Japan.